Effects of the selective 5-HT2A receptor antagonist
MDL 100,907 on MDMA-induced locomotor stimulation in rats
Kehne JH, Ketteler HJ, McCloskey TC,
Sullivan CK, Dudley MW, Schmidt CJ.
Hoechst Marion Roussel, Inc.,
Cincinnati, OH 45215, USA.
Neuropsychopharmacology 1996 Aug;15(2):116-24
ABSTRACT(+/-)3,4-Methylenedioxymethamphetamine (MDMA) releases dopamine and serotonin in vivo and stimulates locomotor activity. Previous work demonstrated that MDMA-stimulated dopamine release could be reduced by the selective 5-HT2A receptor antagonist [R-(+)-a- (2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinem ethanol] (MDL 100,907). In the present study MDL 100,907 significantly reduced MDMA-stimulated locomotion without affecting basal levels of locomotion. Other agents with 5-HT2A antagonist activity (ritanserin, clozapine, MDL 28,133A, or methiothepin), as well as agents that block 5-HT1A-(propranolol), D2-(haloperidol), or D1 receptors (SCH 23390) also reduced MDMA-stimulated locomotion. Intraventricularly administered 5,7-dihydroxytryptamine decreased regional 5-HT levels and attenuated MDMA-stimulated locomotion. These data support the conclusion that serotonin released onto 5-HT2A receptors contributes to MDMA-stimulated locomotion and suggest that MDMA-stimulated locomotion may be useful as an in vivo behavioral measure of 5-HT2A antagonism. The data also support previous reports of contributions of 5-HT1A, D1 and D2 receptors to MDMA-stimulated locomotion. A preliminary time-course analysis indicating time-dependent contributions of different receptors to MDMA-stimulated locomotion suggests the potential utility of this model for characterizing potential atypical antipsychotic compounds.History
MDMA v fenfluramine
Baboons like Ecstasy
Ecstasy/MDMA and cannabis
MDMA, loud noise and the heart
MDMA, HIV and antiretroviral agents
Serotonin, noradrenline and dopamine
MDMA/polydrug users in the UK and Italy
Ecstasy (MDMA), locomotion and the nucleus accumbens